About UMass Boston and DF/HCC
UMass Boston is a Massachusetts public, urban university with an enrollment of 16,756. A Carnegie Research II university, UMass Boston is proudly the most diverse public four-year higher education institution in New England with 46% students of color. As a U.S. Department of Education Title III institution, 56% of UMass Boston undergraduate students are first-generation college students, 40% report speaking a language other than English at home, and 33% receive Pell grants. Promoting educational opportunity is at the core of UMass Boston’s mission. UMass Boston has made a strategic commitment and substantial investments to expanding and strengthening its research and training enterprise.
DF/HCC is the only NCI-designated Comprehensive Cancer Center in Massachusetts. Established as a consortium in 1997, DF/HCC harnesses the enormous expertise and resources of seven Harvard-affiliated institutions into a single integrated force in the fight against cancer: Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Children’s Hospital Boston, Dana-Farber Cancer Institute, Harvard Medical School, Harvard School of Public Health, and Massachusetts General Hospital. DF/HCC’s research agenda is to foster collaboration and team science among its 1,000 members, who have expertise in three broad areas of cancer research: basic research, clinical research, and population science.